The purpose of the Vasculitis Foundation Research Program is to provide one- or two-year seed grants to support pilot studies in researching:
The goals of the Research Program are to improve the quality of life for patients with vasculitis and ultimately find the cause/s and cure for vasculitis.
The Research Program is funded by donations and special fundraising events.
Maximum awards will be $50,000 for 12 months. Some awards will be available for two years at a maximum of $50,000 per year. Among applications with similar scores, preference will be given to applications with total budgets of $50,000 or less, to ensure that the Foundation can support as many investigators, and as many approaches to research in vasculitis as possible. . The Foundation’s hope is that the results of the research supported by the Research Program will lead to, and provide the basis for, much larger multi-year studies that would be funded by larger agencies such as The US National Institutes of Health (NIH).
International Funding Available: The Vasculitis Foundation VF Research Program funds research worldwide.
Applications are reviewed annually. The deadline for submitting applications for the 2015 funding cycle is Monday, August 4, 2014. Awards will be announced in December with funding available January 1, 2015.
To review the grants awarded from 2011-2014, please click here.
PLEASE NOTE: The 2014 application has been updated. Please access the updated instructions and application below. If you have any questions or problems with the application, please email: Joyce Kullman,Executive Director of the Vasculitis Foundation: email@example.com
Click here to access the application instructions.
Click here to access the application.
2012 Consensus Conference
The VF hosted the 2nd International Vasculitis Research Consensus Conference on Friday, April 20, 2012, at the Hilton Chicago, Illinois. Dr. Gary S. Hoffman, Cleveland Clinic Center for Vasculitis Care and Research, functioned as the program moderator and facilitator.
The purpose of the conference was to utilize the combined skills and experience of leading experts in vasculitis from different subspecialties and other scientific fields to evaluate the VF Research Program and explore new areas of inquiry that the Foundation should support over the next five years.
Click here to download the VF Research Consensus Conference Report 2012.
Grants awarded by the Vasculitis Foundation
Rho-kinase Activity in Large Vessel Vasculitis
Lindsay S. Lally, MD, Robert F. Spiera, MD
Department of Medicine, Hospital for Special Surgery, New York City
Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis
Kimberly P. Liang, MD
Division of Rheumatology and Clinical Immunology, University of Pittsburgh
The Role of microRNA in a Novel Mouse Model of Vasculitis
Carola Vinuesa, MD, MSc, PhD
Department of Pathogens and Immunity, Australian National University, Acton, Australia
Development of a uniform histology scoring system for Small Vessel CNS vasculitis in Childhood and Adulthood
Susanne M. Benseler, MD, MSCE, PhD, Department of Pediatrics, Division of Rheumatology, The Hospital for Sick Children
Circulating microparticles as therapeutic targets of plasma exchange in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Paul Brogan, BSc, MBCHB, MRCPCH, MSc, PhD, FRCPCH, Paediatric Rheumatology/Infectious Disease and Microbiology Unit, Institute of Child Health
To Understand Role of 14-3-3- in Giant Cell Arteritis
Ritu Chakravarti, PhD, Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation
Exome sequencing in granulomatosis with polyangiitis (GPA, Wegener’s)
Sharon Chung, MD, MAS, Division of Rheumatology, University of California, San Francisco
Investigating the molecular mechanism for IL-25-driven Act1-dependent eosinophilic vasculitis
Shadi Swaidani, PhD, Cleveland Clinic Lerner Research Institute
Small molecule therapeutics in Giant Cell Arteritis
Cornelia Weyand, MD, PhD, Stanford University School of Medicine
Defining an animal model for the study of Wegener’s Granulomatosis
Felipe Andrade, MD, PhD, The Johns Hopkins University, Baltimore, MD
Reproductive Health in Young Men and Women with Vasculitis
Megan E. B. Clowse, MD, Rheumatology and Immunology, Duke University, Raleigh, NC
Classification and Diagnostic Criteria in Primary Systemic Vasculitis
Raashid Ahmed Luqmani, MD, Nuffield Department of Orthopaedics Rheumatology & Musculoskeletal Science Oxford, United Kingdom
Identification of susceptibility genes in Takayasu’s arteritis
Amr H. Sawalha, MD, Oklahoma City, OK
PARP-1 in CSS-associated IL-10 Promoter Polymorphisms
Jianguo Liu, MD, PhD, Division of Immunobiology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO
Vasculitic T Cells in Giant Cell Arteritis
C.M. Weyand, MD, Emory University, Atlanta, Georgia
An Investigation of the Role of the Innate Immune Response in Kawasaki Disease
Neil Bowles, PhD, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, UT
Investigating the role of the novel Th 17 cells in the pathogenesis of ANCA associated vasculitis and their potential for immunomodulation
Alan Salama, MBBS, PhD, FRCP, Renal Section, Division of Medicine Imperial College London, England
Identification and characterization of immunodominant, conformational epitopes of antineutrophil cytoplasmic antibodies
Antje Mueller, MD, Csernok, MD, Peter Lamphrect, MD
University of Rheumatology, University Hospital Schleswig-Holstein, Campus Luebeck, Germany
Gene Expression Profile of Temporal Arteries of Giant Cell Arteritis
Rula Hajj-Ali, MD, Cleveland Clinic, Cleveland, OH
Environmental Factors in the Pathogenesis of Wegener’s Granulomatosis
Daniel Albert, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
Localized Wegener’s Granulomatosis: Epidemiological, clinical and histopathological characteristics
Peer Malte Aries, MD, and Prof. Wolfgang L. Gross, MD
Department of Rheumatology, University Hospital of Schleswig-Holstein
A Pilot Project Towards Establishment of a US/Canadian Diagnostic Registry of Children with Wegener’s Granulomatosis and Related Vasculitides
David A. Cabral, MBBS, BC Children’s Hospital, Vancouver, BC, Canada
Renal transplantation in Wegener’s granulomatosis: mortality, allograft outcomes and incidence of malignancies from the United Network for Organ Sharing database 1988-2005
Nadine Tanenbaum, MD, Duke University, Raleigh, NC
Identification of novel Wegener’s Granulomatosis Susceptibility Genes
Katherine Siminovitch, PhD, Mount Sinai Hospital, Toronto, ON, Canada
Wegener’s Granulomatosis and Microscopic Polyarteritis Case Control Study in Western Montana
Andrew Zeft, MD, Division of Immunology and Rheumatology, Department of Pediatrics, University of Utah, Salt Lake City, UT
Development of a Measure to Assess Patients’ Adherence to Vasculitis Treatment Regimens
Robert DeVellis, PhD, Associate Director, Arthritis Multidisciplinary Clinical Research Center, University of North Carolina, Chapel Hill, NC
Analysis of NKG2D expression on CD28- T-cells and non-classical MHC-class I antigen expression on antigen-presenting cells as clues to an antigen-driven process and new targets of treatment in Wegener’s granulomatosis
Prof. Wolfgang L. Gross, MD, and Peter Lamprecht, MD
Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, and Rheumaklinik Bad Bramstedt
The role of shear stress in neutrophil proteinase-3 expressionand its importance in vascular injury sites in Wegener’s granulomatosis
Deborah Stearns-Kurosawa, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK
Host-microbial interactions in Wegener’s Granulomatosis: the role of ANCA and S. aureus persistence
Robert Inman, MD, University of Toronto, Canada
Short-Term Cyclophosphamide Therapy in a Cohort of Over 200 Patients
Gary Hoffman, MD, MS and Alexandra Villa-Forte, MD, MPH, The Cleveland Clinic, Cleveland, OH